Pharmacogenetic Testing in the Outpatient Setting in Switzerland: A Descriptive Study Using Swiss Claims Data

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2025 Feb 20

PMID 39976874

Authors

Nina L Wittwer

Christoph R Meier

Carola A Huber

Henriette E Meyer Zu Schwabedissen

Samuel Allemann

Cornelia Schneider

Affiliations

Soon will be listed here.

Abstract

Background: In Switzerland, consumers are exposed to drugs with pharmacogenetic (PGx) recommendations in 78% of cases. Pre-emptive PGx testing for seven drugs (abacavir, carbamazepine, 6-mercaptopurine, azathioprine, 5-fluorouracil, capecitabine, and irinotecan) has been covered by basic health insurance since 2017. PGx testing for other drugs is only covered if it is reactive and prescribed by a clinical pharmacologist. No data are yet available on the implementation of PGx testing in the outpatient setting.

Aim: The objective of this study was to determine the prevalence of ambulatory PGx testing in the Swiss population, to characterize PGx-tested individuals, and to identify the most commonly used drugs before and after PGx testing.

Methods: We assessed the prevalence of PGx testing in Switzerland and characterized individuals who underwent PGx testing between 2017 and 2021 using claims data from a large health insurance company.

Results: Of 894,748 individuals registered for the entire study period, only 817 (0.09%) underwent PGx testing. Those who underwent PGx testing were more frequently female and claimed more drugs and PGx drugs than those who did not undergo PGx testing. The drugs used before and after PGx testing differed, and fewer drugs with reimbursement for pre-emptive PGx testing were included before PGx testing.

Conclusion: In Switzerland, personalized pharmacotherapy has the potential to be improved, as only 0.09% of the studied population underwent PGx testing, despite 77.4% claiming PGx drugs.

References

Westervelt P, Cho K, Bright D, Kisor D . Drug-gene interactions: inherent variability in drug maintenance dose requirements. P T. 2014; 39(9):630-7. PMC: 4159057. View

Hahn M, Roll S . The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug-Drug Interactions: Drug-Gene, Drug-Gene-Gene and Drug-Drug-Gene Interactions. Pharmaceuticals (Basel). 2021; 14(5). PMC: 8160673. DOI: 10.3390/ph14050487. View

Lee J, Aminkeng F, Bhavsar A, Shaw K, Carleton B, Hayden M . The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin Genet. 2014; 86(1):21-8. PMC: 4233969. DOI: 10.1111/cge.12392. View

Reisberg S, Krebs K, Lepamets M, Kals M, Magi R, Metsalu K . Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions. Genet Med. 2018; 21(6):1345-1354. PMC: 6752278. DOI: 10.1038/s41436-018-0337-5. View

Ji Y, Skierka J, Blommel J, Moore B, VanCuyk D, Bruflat J . Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. J Mol Diagn. 2016; 18(3):438-445. PMC: 4851731. DOI: 10.1016/j.jmoldx.2016.01.003. View

Van Driest S, Shi Y, Bowton E, Schildcrout J, Peterson J, Pulley J . Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2013; 95(4):423-31. PMC: 3961508. DOI: 10.1038/clpt.2013.229. View

Wang L, Scherer S, Bielinski S, Muzny D, Jones L, Black 3rd J . Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. Genet Med. 2022; 24(5):1062-1072. PMC: 9272414. DOI: 10.1016/j.gim.2022.01.022. View

McInnes G, Lavertu A, Sangkuhl K, Klein T, Whirl-Carrillo M, Altman R . Pharmacogenetics at Scale: An Analysis of the UK Biobank. Clin Pharmacol Ther. 2020; 109(6):1528-1537. PMC: 8144239. DOI: 10.1002/cpt.2122. View

Lunenburg C, Hauser A, Ishtiak-Ahmed K, Gasse C . Primary Care Prescription Drug Use and Related Actionable Drug-Gene Interactions in the Danish Population. Clin Transl Sci. 2020; 13(4):798-806. PMC: 7359946. DOI: 10.1111/cts.12768. View

10.

Alshabeeb M, Deneer V, Khan A, Asselbergs F . Use of Pharmacogenetic Drugs by the Dutch Population. Front Genet. 2019; 10:567. PMC: 6614185. DOI: 10.3389/fgene.2019.00567. View

11.

Bank P, Swen J, Guchelaar H . Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands. BMC Med. 2019; 17(1):110. PMC: 6567386. DOI: 10.1186/s12916-019-1342-5. View

12.

van der Wouden C, Bank P, Ozokcu K, Swen J, Guchelaar H . Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact. Genes (Basel). 2019; 10(6). PMC: 6628264. DOI: 10.3390/genes10060416. View

13.

Krebs K, Milani L . Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. Hum Genomics. 2019; 13(1):39. PMC: 6712791. DOI: 10.1186/s40246-019-0229-z. View

14.

Crews K, Hicks J, Pui C, Relling M, Evans W . Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther. 2012; 92(4):467-75. PMC: 3589526. DOI: 10.1038/clpt.2012.120. View

15.

Swen J, van der Wouden C, Manson L, Abdullah-Koolmees H, Blagec K, Blagus T . A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023; 401(10374):347-356. DOI: 10.1016/S0140-6736(22)01841-4. View

16.

Vassy J, Chun S, Advani S, Ludin S, Smith J, Alligood E . Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review. Clin Pharmacol Ther. 2018; 106(2):360-373. PMC: 8083115. DOI: 10.1002/cpt.1223. View

17.

Alfirevic A, Pirmohamed M, Marinovic B, Harcourt-Smith L, Jorgensen A, Cooper T . Genetic testing for prevention of severe drug-induced skin rash. Cochrane Database Syst Rev. 2019; 7:CD010891. PMC: 6636675. DOI: 10.1002/14651858.CD010891.pub2. View

18.

David V, Fylan B, Bryant E, Smith H, Sagoo G, Rattray M . An Analysis of Pharmacogenomic-Guided Pathways and Their Effect on Medication Changes and Hospital Admissions: A Systematic Review and Meta-Analysis. Front Genet. 2021; 12:698148. PMC: 8362615. DOI: 10.3389/fgene.2021.698148. View

19.

Wittwer N, Meier C, Huber C, Zu Schwabedissen H, Allemann S, Schneider C . Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Switzerland: A Descriptive Study Using the Helsana Database. Pharmgenomics Pers Med. 2022; 15:967-976. PMC: 9701506. DOI: 10.2147/PGPM.S382214. View

20.

Begre U, Jorger M, Aebi S, Amstutz U, Largiader C . Clinical Implementation of Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland. Front Pharmacol. 2022; 13:885259. PMC: 9159275. DOI: 10.3389/fphar.2022.885259. View